Introduction: The Mayotte Cancer Screening Network (Rédéca) has been organizing cervical cancer screening since 2010. This article presents the main results of the activities and follow-up from its second screening campaign, conducted from 2013 to 2015. Methods: Screening is offered to all women aged 25 to 65, with or without health insurance, through an invitation system managed primarily by healthcare professionals affiliated with the network and by Rédéca health mediators. Cytological tests are performed using liquid-based cytology and sent to the Paris region for analysis. The network ensures diagnostic and therapeutic follow-up in accordance with national recommendations, in partnership with the Mayotte Hospital Center (CHM). Results: At the conclusion of the second cervical cancer screening campaign (2013–2015), the coverage rate was 39% versus 36% at the conclusion of the previous campaign (2010–2012). ASCUS (atypical squamous cells of undetermined significance) cytological lesions were the most common abnormality among women aged 25 to 49. High-grade lesions were 2.5 times more prevalent than the average observed in four pilot departments in mainland France (Alsace, Isère, Indre-et-Loire, and Maine-et-Loire): 7.1 HSIL smears per 1,000 women screened in Mayotte in 2014 versus 2.8 HSIL smears per 1,000 women screened across all four metropolitan departments between 2010 and 2014. Nearly half of the abnormal Pap smears followed by histology showed high-grade cytological lesions (HSIL). During the second screening campaign, 6 cancers were detected as a result of the screening organized by Rédéca Mayotte. Conclusion: The results provide insights into the high prevalence of precancerous cervical lesions in Mayotte, as well as the resources required for their management. They underscore the importance of an organized screening structure in Mayotte to increase screening coverage, taking into account the significant disparities in healthcare utilization and access that exist in the region, and in anticipation of the nationwide rollout of cervical cancer screening across France in 2018.